Terms: = Kidney tumors AND ELF4, MEF, 2000, ENSG00000102034, ELFR, RP3-510O21_2, Q99607 AND Treatment
12483 results:
1. Gallic acid suppresses the progression of clear cell renal cell carcinoma through inducing autophagy via the PI3K/Akt/Atg16L1 signaling pathway.
Zhang T; Zhang X; Fei Y; Lu J; Zhou D; Zhang L; Fan S; Zhou J; Liang C; Su Y
Int J Oncol; 2024 Jul; 65(1):. PubMed ID: 38818827
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.
Yamashita S; Hamamoto S; Furukawa J; Fujita K; Takahashi M; Miyake M; Ito N; Iwamoto H; Kohjimoto Y; Hara I
Sci Rep; 2024 May; 14(1):12398. PubMed ID: 38811687
[TBL] [Abstract] [Full Text] [Related]
3. Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma.
Mehra R; Nallandhighal S; Cotta B; Knuth Z; Su F; Kasputis A; Zhang Y; Wang R; Cao X; Udager AM; Dhanasekaran SM; Cieslik MP; Morgan TM; Salami SS
JCO Precis Oncol; 2024 May; 8():e2300565. PubMed ID: 38810179
[TBL] [Abstract] [Full Text] [Related]
4. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway.
Zhang ZY; Xu JH; Zhang JL; Lin YX; Ou-Yang J
BMC Cancer; 2024 May; 24(1):650. PubMed ID: 38802739
[TBL] [Abstract] [Full Text] [Related]
5. Highly variable biological effects of statins on cancer, non-cancer, and stem cells in vitro.
Gbelcová H; Rimpelová S; Jariabková A; Macášek P; Priščáková P; Ruml T; Šáchová J; Kubovčiak J; Kolář M; Vítek L
Sci Rep; 2024 May; 14(1):11830. PubMed ID: 38782983
[TBL] [Abstract] [Full Text] [Related]
6. Disparities in treatment patterns and mortality in prostate cancer: Interaction between Black race and end-stage kidney disease.
Sarabu N; Dong W; Koroukian SM
Cancer Med; 2024 May; 13(10):e7027. PubMed ID: 38770622
[TBL] [Abstract] [Full Text] [Related]
7. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
[TBL] [Abstract] [Full Text] [Related]
8. Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib.
Lin Z; Xiao S; Qi Y; Guo J; Lu L
J Cancer Res Clin Oncol; 2024 May; 150(5):262. PubMed ID: 38762825
[TBL] [Abstract] [Full Text] [Related]
9. End-stage renal disease after renal cancer surgery: risk factors and overall survival.
Åkerlund J; Ljungberg B; Lundstam S; Peeker R; Holmberg E; Månsson M; Grenabo Bergdahl A
Scand J Urol; 2024 May; 59():109-116. PubMed ID: 38747153
[TBL] [Abstract] [Full Text] [Related]
10. Endoscopic intervention versus radical nephroureterectomy for the management of localized upper urinary tract urothelial carcinoma: a systematic review and meta-analysis of comparative studies.
Giulioni C; Brocca C; Tramanzoli P; Stramucci S; Mantovan M; Perpepaj L; Cicconofri A; Gauhar V; Merseburger AS; Galosi AB; Castellani D
World J Urol; 2024 May; 42(1):318. PubMed ID: 38743260
[TBL] [Abstract] [Full Text] [Related]
11. Single-layer versus double-layer renorrhaphy technique during robot-assisted partial nephrectomy: impact on perioperative outcomes, complications, and functional outcomes.
Bertolo R; Ditonno F; Veccia A; DE Marco V; Migliorini F; Porcaro AB; Rizzetto R; Cerruto MA; Autorino R; Antonelli A
Minerva Urol Nephrol; 2024 Apr; 76(2):176-184. PubMed ID: 38742552
[TBL] [Abstract] [Full Text] [Related]
12. Projected estimates of cancer in Canada in 2024.
Brenner DR; Gillis J; Demers AA; Ellison LF; Billette JM; Zhang SX; Liu JL; Woods RR; Finley C; Fitzgerald N; Saint-Jacques N; Shack L; Turner D;
CMAJ; 2024 May; 196(18):E615-E623. PubMed ID: 38740416
[TBL] [Abstract] [Full Text] [Related]
13. Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.
Liu K; Li Q; Lu X; Fan X; Yang Y; Xie W; Kang J; Sun S; Zhao J
Pharm Biol; 2024 Dec; 62(1):404-422. PubMed ID: 38739082
[TBL] [Abstract] [Full Text] [Related]
14. SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Xu X; Lin J; Wang J; Wang Y; Zhu Y; Wang J; Guo J
Hum Vaccin Immunother; 2024 Dec; 20(1):2350101. PubMed ID: 38738709
[TBL] [Abstract] [Full Text] [Related]
15. Receptor Targeting Using Copolymer-Modified Gold Nanoparticles for pCMV-Luc Gene Delivery to Liver Cancer Cells In Vitro.
Zenze M; Singh M
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732235
[TBL] [Abstract] [Full Text] [Related]
16. Clinical features of patients with carcinoma soft tissue metastases as surgical indications: a retrospective cohort study.
Morinaga S; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Taniguchi Y; Asano Y; Nojima T; Tsuchiya H
BMC Cancer; 2024 May; 24(1):577. PubMed ID: 38730358
[TBL] [Abstract] [Full Text] [Related]
17. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review.
Turjap M; Pelcová M; Gregorová J; Šmak P; Martin H; Štingl J; Peš O; Juřica J
Ther Drug Monit; 2024 Jun; 46(3):321-331. PubMed ID: 38723115
[TBL] [Abstract] [Full Text] [Related]
18. IL-2RG as a possible immunotherapeutic target in CRC predicting poor prognosis and regulated by miR-7-5p and miR-26b-5p.
Gharib E; Rejali L; Piroozkhah M; Zonoobi E; Nasrabadi PN; Arabsorkhi Z; Baghdar K; Shams E; Sadeghi A; Kuppen PJK; Salehi Z; Nazemalhosseini-Mojarad E
J Transl Med; 2024 May; 22(1):439. PubMed ID: 38720389
[TBL] [Abstract] [Full Text] [Related]
19. CXCR2/Snail-1-Induced Epithelial-Mesenchymal Transition in the Formation and Progression of RCC with Inferior Vena Cava Tumour Thrombus.
Wang L; Gao J; Zheng S; Luo Z; Xu Z; Che H; Wang Z
Arch Esp Urol; 2024 Apr; 77(3):292-302. PubMed ID: 38715171
[TBL] [Abstract] [Full Text] [Related]
20. Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
J Cell Mol Med; 2024 May; 28(9):e18329. PubMed ID: 38693863
[TBL] [Abstract] [Full Text] [Related]
[Next]
